Q-omics provides the consensus-scored THG1L profile across patient tissues and cancer cell-line models. THG1L expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, THG1L is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, THG1L protein abundance shows 22,641 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRC, and UCEC as cancer lineages where THG1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THG1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THG1L survival associations across molecular data types. THG1L RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THG1L RNA expression–survival associations across cancer types. High THG1L expression shows unfavorable associations in KIRP, HNSC, LUAD and ACC, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for THG1L RNA expression.
This table summarizes THG1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for THG1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THG1L shows lower tumor expression in KICH and UCEC and higher tumor expression in KIRC, KIRP, LIHC and COAD. The KIRC box plot shows higher THG1L RNA expression in tumor versus normal tissue (log2 FC = +1.079, t-test p < 0.001).
This table shows molecular features associated with THG1L in patient tissues and cancer cell lines. In patient samples, THG1L shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, THG1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
